Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Icon Interventional Systems was a medical device company specializing in the development of advanced interventional cardiology technologies. The company is best known for its proprietary Nuloy alloy, a high-performance cobalt-chromium formulation designed specifically for the manufacture of coronary stents. This technology enabled the creation of stents with thinner struts and increased radiopacity, improving both deliverability and visibility during clinical procedures. By addressing the mechanical limitations of traditional stainless steel, Icon's innovations aimed to improve patient outcomes in percutaneous coronary interventions. The company was acquired by Abbott in 2007 to bolster its vascular device portfolio and integrate the Nuloy technology into its next-generation stent platforms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Icon Interventional Systems.